Subcutaneous vs Intravenous Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
Haematologica 2022 Mar 31;[EPub Ahead of Print], SZ Usmani, H Nahi, W Legiec, S Grosicki, V Vorobyev, I Spicka, V Hungria, S Korenkova, NJ Bahlis, M Flogegard, J Bladé, P Moreau, M Kaiser, S Iida, J Laubach, H Magen, M Cavo, C Hulin, D White, V De Stefano, K Lantz, L O'Rourke, C Heuck, M Delioukina, X Qin, I Nnane, M Qi, MV MateosFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.